S&P 500   0.63 (+2.44%)
DOW   0.63 (+2.44%)
BA   187.94 (+4.43%)
S&P 500   0.63 (+2.44%)
DOW   0.63 (+2.44%)
BA   187.94 (+4.43%)
S&P 500   0.63 (+2.44%)
DOW   0.63 (+2.44%)
BA   187.94 (+4.43%)
S&P 500   0.63 (+2.44%)
DOW   0.63 (+2.44%)
BA   187.94 (+4.43%)
Log in

NASDAQ:EYEGEyegate Pharmaceuticals Competitors & Alternatives

$5.18
+0.14 (+2.78 %)
(As of 07/15/2020 04:00 PM ET)
Add
Compare
Today's Range
$4.83
Now: $5.18
$5.20
50-Day Range
$4.66
MA: $5.05
$5.60
52-Week Range
$2.25
Now: $5.18
$12.89
Volume26,200 shs
Average Volume66,082 shs
Market Capitalization$23.97 million
P/E RatioN/A
Dividend YieldN/A
Beta1.7

Competitors

Eyegate Pharmaceuticals (NASDAQ:EYEG) Vs. ORMP, TRVI, CFRX, CKPT, VCNX, and DMAC

Should you be buying EYEG stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Eyegate Pharmaceuticals, including Oramed Pharmaceuticals (ORMP), Trevi Therapeutics (TRVI), ContraFect (CFRX), Checkpoint Therapeutics (CKPT), Vaccinex (VCNX), and DiaMedica Therapeutics (DMAC).

Oramed Pharmaceuticals (NASDAQ:ORMP) and Eyegate Pharmaceuticals (NASDAQ:EYEG) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, dividends, analyst recommendations, risk, institutional ownership, earnings and valuation.

Valuation and Earnings

This table compares Oramed Pharmaceuticals and Eyegate Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oramed Pharmaceuticals$2.70 million35.38$-14,350,000.00$0.824.95
Eyegate Pharmaceuticals$2.69 million8.91$-7,100,000.00($2.23)-2.32

Eyegate Pharmaceuticals has lower revenue, but higher earnings than Oramed Pharmaceuticals. Eyegate Pharmaceuticals is trading at a lower price-to-earnings ratio than Oramed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Oramed Pharmaceuticals and Eyegate Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Oramed Pharmaceuticals00303.00
Eyegate Pharmaceuticals00103.00

Oramed Pharmaceuticals presently has a consensus target price of $9.8333, indicating a potential upside of 142.20%. Eyegate Pharmaceuticals has a consensus target price of $12.00, indicating a potential upside of 131.66%. Given Oramed Pharmaceuticals' higher probable upside, research analysts plainly believe Oramed Pharmaceuticals is more favorable than Eyegate Pharmaceuticals.

Profitability

This table compares Oramed Pharmaceuticals and Eyegate Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Oramed Pharmaceuticals-230.07%-28.75%-17.58%
Eyegate PharmaceuticalsN/A-133.93%-94.32%

Risk and Volatility

Oramed Pharmaceuticals has a beta of 1.62, meaning that its stock price is 62% more volatile than the S&P 500. Comparatively, Eyegate Pharmaceuticals has a beta of 1.7, meaning that its stock price is 70% more volatile than the S&P 500.

Insider & Institutional Ownership

2.6% of Oramed Pharmaceuticals shares are held by institutional investors. Comparatively, 42.0% of Eyegate Pharmaceuticals shares are held by institutional investors. 16.1% of Oramed Pharmaceuticals shares are held by insiders. Comparatively, 57.0% of Eyegate Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Oramed Pharmaceuticals beats Eyegate Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

Trevi Therapeutics (NASDAQ:TRVI) and Eyegate Pharmaceuticals (NASDAQ:EYEG) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, risk, analyst recommendations, earnings, valuation, dividends and institutional ownership.

Institutional and Insider Ownership

78.3% of Trevi Therapeutics shares are owned by institutional investors. Comparatively, 42.0% of Eyegate Pharmaceuticals shares are owned by institutional investors. 47.3% of Trevi Therapeutics shares are owned by insiders. Comparatively, 57.0% of Eyegate Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Trevi Therapeutics and Eyegate Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Trevi TherapeuticsN/A-51.74%-46.55%
Eyegate PharmaceuticalsN/A-133.93%-94.32%

Analyst Recommendations

This is a summary of current ratings and target prices for Trevi Therapeutics and Eyegate Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Trevi Therapeutics00203.00
Eyegate Pharmaceuticals00103.00

Trevi Therapeutics currently has a consensus target price of $11.00, suggesting a potential upside of 114.01%. Eyegate Pharmaceuticals has a consensus target price of $12.00, suggesting a potential upside of 131.66%. Given Eyegate Pharmaceuticals' higher possible upside, analysts plainly believe Eyegate Pharmaceuticals is more favorable than Trevi Therapeutics.

Risk & Volatility

Trevi Therapeutics has a beta of 0.58, suggesting that its share price is 42% less volatile than the S&P 500. Comparatively, Eyegate Pharmaceuticals has a beta of 1.7, suggesting that its share price is 70% more volatile than the S&P 500.

Valuation & Earnings

This table compares Trevi Therapeutics and Eyegate Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Trevi TherapeuticsN/AN/A$-26,050,000.00($2.28)-2.25
Eyegate Pharmaceuticals$2.69 million8.91$-7,100,000.00($2.23)-2.32

Eyegate Pharmaceuticals has higher revenue and earnings than Trevi Therapeutics. Eyegate Pharmaceuticals is trading at a lower price-to-earnings ratio than Trevi Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Eyegate Pharmaceuticals beats Trevi Therapeutics on 7 of the 11 factors compared between the two stocks.

ContraFect (NASDAQ:CFRX) and Eyegate Pharmaceuticals (NASDAQ:EYEG) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, risk, analyst recommendations, earnings, valuation, dividends and institutional ownership.

Profitability

This table compares ContraFect and Eyegate Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ContraFectN/A-128.80%-48.48%
Eyegate PharmaceuticalsN/A-133.93%-94.32%

Risk & Volatility

ContraFect has a beta of 1.08, suggesting that its share price is 8% more volatile than the S&P 500. Comparatively, Eyegate Pharmaceuticals has a beta of 1.7, suggesting that its share price is 70% more volatile than the S&P 500.

Institutional and Insider Ownership

37.3% of ContraFect shares are owned by institutional investors. Comparatively, 42.0% of Eyegate Pharmaceuticals shares are owned by institutional investors. 3.7% of ContraFect shares are owned by insiders. Comparatively, 57.0% of Eyegate Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of current ratings and target prices for ContraFect and Eyegate Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ContraFect00403.00
Eyegate Pharmaceuticals00103.00

ContraFect currently has a consensus target price of $16.00, suggesting a potential upside of 171.19%. Eyegate Pharmaceuticals has a consensus target price of $12.00, suggesting a potential upside of 131.66%. Given ContraFect's higher possible upside, equities analysts plainly believe ContraFect is more favorable than Eyegate Pharmaceuticals.

Valuation & Earnings

This table compares ContraFect and Eyegate Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ContraFectN/AN/A$-12,790,000.00$1.115.32
Eyegate Pharmaceuticals$2.69 million8.91$-7,100,000.00($2.23)-2.32

Eyegate Pharmaceuticals has higher revenue and earnings than ContraFect. Eyegate Pharmaceuticals is trading at a lower price-to-earnings ratio than ContraFect, indicating that it is currently the more affordable of the two stocks.

Summary

ContraFect beats Eyegate Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

Eyegate Pharmaceuticals (NASDAQ:EYEG) and Checkpoint Therapeutics (NASDAQ:CKPT) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, risk, valuation, profitability and institutional ownership.

Analyst Recommendations

This is a summary of current recommendations for Eyegate Pharmaceuticals and Checkpoint Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Eyegate Pharmaceuticals00103.00
Checkpoint Therapeutics00303.00

Eyegate Pharmaceuticals presently has a consensus price target of $12.00, suggesting a potential upside of 131.66%. Checkpoint Therapeutics has a consensus price target of $14.3333, suggesting a potential upside of 753.17%. Given Checkpoint Therapeutics' higher possible upside, analysts clearly believe Checkpoint Therapeutics is more favorable than Eyegate Pharmaceuticals.

Earnings & Valuation

This table compares Eyegate Pharmaceuticals and Checkpoint Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Eyegate Pharmaceuticals$2.69 million8.91$-7,100,000.00($2.23)-2.32
Checkpoint Therapeutics$1.71 million54.09$-24,710,000.00($0.70)-2.40

Eyegate Pharmaceuticals has higher revenue and earnings than Checkpoint Therapeutics. Checkpoint Therapeutics is trading at a lower price-to-earnings ratio than Eyegate Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Eyegate Pharmaceuticals has a beta of 1.7, suggesting that its share price is 70% more volatile than the S&P 500. Comparatively, Checkpoint Therapeutics has a beta of 1.9, suggesting that its share price is 90% more volatile than the S&P 500.

Profitability

This table compares Eyegate Pharmaceuticals and Checkpoint Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Eyegate PharmaceuticalsN/A-133.93%-94.32%
Checkpoint Therapeutics-949.53%-182.15%-111.25%

Institutional and Insider Ownership

42.0% of Eyegate Pharmaceuticals shares are held by institutional investors. Comparatively, 10.3% of Checkpoint Therapeutics shares are held by institutional investors. 57.0% of Eyegate Pharmaceuticals shares are held by company insiders. Comparatively, 9.8% of Checkpoint Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Eyegate Pharmaceuticals beats Checkpoint Therapeutics on 8 of the 13 factors compared between the two stocks.

Eyegate Pharmaceuticals (NASDAQ:EYEG) and Vaccinex (NASDAQ:VCNX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, risk, valuation, profitability and institutional ownership.

Analyst Recommendations

This is a summary of current recommendations for Eyegate Pharmaceuticals and Vaccinex, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Eyegate Pharmaceuticals00103.00
Vaccinex00103.00

Eyegate Pharmaceuticals presently has a consensus price target of $12.00, suggesting a potential upside of 131.66%. Vaccinex has a consensus price target of $22.00, suggesting a potential upside of 304.41%. Given Vaccinex's higher possible upside, analysts clearly believe Vaccinex is more favorable than Eyegate Pharmaceuticals.

Earnings & Valuation

This table compares Eyegate Pharmaceuticals and Vaccinex's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Eyegate Pharmaceuticals$2.69 million8.91$-7,100,000.00($2.23)-2.32
Vaccinex$520,000.00174.13$-31,860,000.00($2.47)-2.20

Eyegate Pharmaceuticals has higher revenue and earnings than Vaccinex. Eyegate Pharmaceuticals is trading at a lower price-to-earnings ratio than Vaccinex, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Eyegate Pharmaceuticals has a beta of 1.7, suggesting that its share price is 70% more volatile than the S&P 500. Comparatively, Vaccinex has a beta of 1.2, suggesting that its share price is 20% more volatile than the S&P 500.

Profitability

This table compares Eyegate Pharmaceuticals and Vaccinex's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Eyegate PharmaceuticalsN/A-133.93%-94.32%
VaccinexN/A-2,277.96%-436.90%

Institutional and Insider Ownership

42.0% of Eyegate Pharmaceuticals shares are held by institutional investors. Comparatively, 8.6% of Vaccinex shares are held by institutional investors. 57.0% of Eyegate Pharmaceuticals shares are held by company insiders. Comparatively, 68.6% of Vaccinex shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Eyegate Pharmaceuticals beats Vaccinex on 8 of the 11 factors compared between the two stocks.

Eyegate Pharmaceuticals (NASDAQ:EYEG) and DiaMedica Therapeutics (NASDAQ:DMAC) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, valuation, analyst recommendations, risk, institutional ownership and dividends.

Risk & Volatility

Eyegate Pharmaceuticals has a beta of 1.7, meaning that its stock price is 70% more volatile than the S&P 500. Comparatively, DiaMedica Therapeutics has a beta of 2.86, meaning that its stock price is 186% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings for Eyegate Pharmaceuticals and DiaMedica Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Eyegate Pharmaceuticals00103.00
DiaMedica Therapeutics00303.00

Eyegate Pharmaceuticals currently has a consensus price target of $12.00, suggesting a potential upside of 131.66%. DiaMedica Therapeutics has a consensus price target of $14.3333, suggesting a potential upside of 142.94%. Given DiaMedica Therapeutics' higher possible upside, analysts plainly believe DiaMedica Therapeutics is more favorable than Eyegate Pharmaceuticals.

Profitability

This table compares Eyegate Pharmaceuticals and DiaMedica Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Eyegate PharmaceuticalsN/A-133.93%-94.32%
DiaMedica TherapeuticsN/A-92.84%-83.19%

Institutional and Insider Ownership

42.0% of Eyegate Pharmaceuticals shares are held by institutional investors. Comparatively, 20.7% of DiaMedica Therapeutics shares are held by institutional investors. 57.0% of Eyegate Pharmaceuticals shares are held by insiders. Comparatively, 12.6% of DiaMedica Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Eyegate Pharmaceuticals and DiaMedica Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Eyegate Pharmaceuticals$2.69 million8.91$-7,100,000.00($2.23)-2.32
DiaMedica Therapeutics$500,000.00166.84$-10,650,000.00($0.89)-6.63

Eyegate Pharmaceuticals has higher revenue and earnings than DiaMedica Therapeutics. DiaMedica Therapeutics is trading at a lower price-to-earnings ratio than Eyegate Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

DiaMedica Therapeutics beats Eyegate Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Oramed Pharmaceuticals logo
ORMP
Oramed Pharmaceuticals
1.3$4.06+11.6%$95.52 million$2.70 million-12.30Analyst Report
High Trading Volume
Heavy News Reporting
TRVI
Trevi Therapeutics
1.5$5.14+4.3%$91.72 millionN/A-3.01Analyst Report
ContraFect logo
CFRX
ContraFect
1.4$5.90+7.5%$91.21 millionN/A-1.74Heavy News Reporting
Checkpoint Therapeutics logo
CKPT
Checkpoint Therapeutics
1.2$1.68+3.9%$90.85 million$1.71 million-2.90Analyst Report
VCNX
Vaccinex
2.0$5.44+14.5%$90.55 million$520,000.00-2.52High Trading Volume
Heavy News Reporting
DMAC
DiaMedica Therapeutics
1.1$5.90+1.7%$89.08 million$500,000.00-7.28
Unum Therapeutics logo
UMRX
Unum Therapeutics
1.3$2.84+15.5%$88.50 million$22.50 million-3.30Analyst Revision
Evoke Pharma logo
EVOK
Evoke Pharma
1.4$3.63+5.5%$87.93 millionN/A-12.52
AcelRx Pharmaceuticals logo
ACRX
AcelRx Pharmaceuticals
1.9$1.08+2.8%$87.22 million$2.29 million-1.54Analyst Downgrade
MRKR
TapImmune
1.4$1.76+0.6%$86.08 million$210,000.00-3.59Heavy News Reporting
MIST
Milestone Pharmaceuticals
1.5$3.34+5.4%$85.22 millionN/A-1.12
Zynerba Pharmaceuticals logo
ZYNE
Zynerba Pharmaceuticals
1.7$3.41+1.2%$85.08 million$90,000.00-2.17
Aclaris Therapeutics logo
ACRS
Aclaris Therapeutics
1.5$2.03+1.5%$85.00 million$4.23 million-0.60
SAVA
Cassava Sciences
1.1$3.65+0.3%$84.00 millionN/A-15.87Heavy News Reporting
Clearside Biomedical logo
CLSD
Clearside Biomedical
1.3$1.68+2.4%$83.91 million$2.17 million-3.65Heavy News Reporting
resTORbio logo
TORC
resTORbio
1.4$2.35+3.4%$82.73 millionN/A-1.08
MNPR
Monopar Therapeutics
1.5$7.94+0.3%$80.68 millionN/A-17.64
ONCY
Oncolytics Biotech
1.2$1.98+3.5%$80.15 millionN/A-2.25Analyst Downgrade
High Trading Volume
MREO
Mereo BioPharma Group
0.5$2.99+0.3%$76.94 millionN/A-1.20
Sesen Bio logo
SESN
Sesen Bio
1.2$0.67+0.7%$76.61 million$430,000.00-0.83
Adamas Pharmaceuticals logo
ADMS
Adamas Pharmaceuticals
1.5$2.68+1.1%$75.46 million$54.64 million-0.81Heavy News Reporting
AVEO Pharmaceuticals logo
AVEO
AVEO Pharmaceuticals
2.1$4.24+1.4%$73.97 million$28.80 million6.95
Catalyst Biosciences logo
CBIO
Catalyst Biosciences
1.4$5.83+4.1%$70.41 million$10,000.00-1.57Analyst Report
OncoSec Medical logo
ONCS
OncoSec Medical
1.3$3.05+5.9%$70.25 millionN/A0.00Analyst Report
High Trading Volume
Heavy News Reporting
Proteostasis Therapeutics logo
PTI
Proteostasis Therapeutics
1.1$1.27+1.6%$69.36 million$5 million-1.20
ENLV
Enlivex Therapeutics
1.3$5.10+1.8%$68.48 millionN/A-7.08Analyst Downgrade
SCYNEXIS logo
SCYX
SCYNEXIS
1.6$0.69+1.4%$68.18 million$120,000.00-1.17High Trading Volume
Capricor Therapeutics logo
CAPR
Capricor Therapeutics
1.3$4.08+14.2%$66.45 million$1 million-2.46Analyst Upgrade
Moleculin Biotech logo
MBRX
Moleculin Biotech
1.2$1.07+27.1%$64.63 millionN/A-4.86High Trading Volume
Heavy News Reporting
ACST
Acasti Pharma
1.4$0.69+2.9%$63.82 millionN/A-1.82
MITO
Stealth BioTherapeutics
1.3$1.82+1.6%$63.76 million$21.09 million-1.06
Lipocine logo
LPCN
Lipocine
1.3$1.23+1.6%$61.77 million$170,000.00-2.46Heavy News Reporting
Aridis Pharmaceuticals logo
ARDS
Aridis Pharmaceuticals
1.3$7.08+7.5%$61.55 million$1.02 million-2.17Analyst Upgrade
High Trading Volume
Synlogic logo
SYBX
Synlogic
1.6$1.85+1.1%$60.75 million$2.22 million-1.11
VERONA PHARMA P/S logo
VRNA
VERONA PHARMA P/S
1.6$4.45+6.1%$58.59 millionN/A-1.28
IMMUTEP LTD/S logo
IMMP
IMMUTEP LTD/S
1.3$1.10+1.8%$56.94 million$5.36 million0.00
ASLAN PHARMACEU/ADR logo
ASLN
ASLAN PHARMACEU/ADR
1.1$1.75+2.3%$56.09 million$3 million-1.61Earnings Announcement
Analyst Upgrade
Analyst Revision
Heavy News Reporting
Citius Pharmaceuticals logo
CTXR
Citius Pharmaceuticals
1.5$1.19+3.4%$54.23 millionN/A-1.49
Eyenovia logo
EYEN
Eyenovia
1.1$2.61+1.9%$51.62 millionN/A-1.93
Soligenix logo
SNGX
Soligenix
1.4$1.94+1.5%$51.56 million$4.60 million-2.69
Vascular Biogenics logo
VBLT
Vascular Biogenics
1.3$1.22+0.8%$51.15 million$560,000.00-2.10
Cumberland Pharmaceuticals logo
CPIX
Cumberland Pharmaceuticals
2.4$3.18+0.6%$49.34 million$47.53 million-10.60
Adamis Pharmaceuticals logo
ADMP
Adamis Pharmaceuticals
1.4$0.66+6.1%$48.42 million$22.11 million-1.28High Trading Volume
Infinity Pharmaceuticals logo
INFI
Infinity Pharmaceuticals
1.3$0.82+1.0%$47.94 million$3.05 million-1.06High Trading Volume
Diffusion Pharmaceuticals logo
DFFN
Diffusion Pharmaceuticals
1.3$0.98+10.2%$47.33 millionN/A-0.56
ETTX
Entasis Therapeutics
2.5$3.10+1.3%$45.58 million$7 million-0.89Analyst Report
High Trading Volume
SEEL
Seelos Therapeutics
1.3$1.01+0.0%$45.40 million$380,000.000.00
Zosano Pharma logo
ZSAN
Zosano Pharma
1.4$0.81+0.1%$44.12 millionN/A-0.45
Merrimack Pharmaceuticals logo
MACK
Merrimack Pharmaceuticals
1.4$3.22+3.7%$42.95 millionN/A0.00Heavy News Reporting
Novan logo
NOVN
Novan
1.2$0.50+1.0%$42.84 million$4.90 million-0.47
This page was last updated on 7/15/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.